摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(1-十一烷基)三苯基鏻溴化物 | 60669-22-9

中文名称
(1-十一烷基)三苯基鏻溴化物
中文别名
——
英文名称
n-undecyltriphenylphosphonium bromide
英文别名
undecyltriphenylphosphonium bromide;triphenyl(undecyl)phosphonium bromide;undecanyltriphenylphosphonium bromide;Triphenyl(undecyl)phosphanium bromide;triphenyl(undecyl)phosphanium;bromide
(1-十一烷基)三苯基鏻溴化物化学式
CAS
60669-22-9
化学式
Br*C29H38P
mdl
——
分子量
497.498
InChiKey
AELWOFMTABHNQJ-UHFFFAOYSA-M
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4.52
  • 重原子数:
    31
  • 可旋转键数:
    13
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.38
  • 拓扑面积:
    0
  • 氢给体数:
    0
  • 氢受体数:
    1

安全信息

  • 安全说明:
    S26,S36
  • 危险类别码:
    R36/37/38
  • 海关编码:
    2931900090

SDS

SDS:43003618e6df63033af76fdac0b90962
查看

反应信息

  • 作为反应物:
    描述:
    (1-十一烷基)三苯基鏻溴化物盐酸正丁基锂甲酸 、 samarium diiodide 、 palladium 10% on activated carbon 、 氢气二异丁基氢化铝 作用下, 以 四氢呋喃甲醇甲苯叔丁醇 为溶剂, 反应 37.0h, 生成 糖脂
    参考文献:
    名称:
    A flexible approach to construct three contiguous chiral centers of sphingolipids, and asymmetric synthesis of d-ribo-phytosphingosine and its derivatives
    摘要:
    An efficient approach to build the three contiguous stereogenic centers of sphingosine unit starting from cheap glutamic acid is described. The key step of this approach is the SmI2-mediated cross-coupling of chiral N-tert-butanesulfinyl imine 11 with sterically hindered aliphatic aldehyde 9 or 21 to construct hydroxymethyl beta-amino alcohol 10 or 22 in high diastereoselectivity (>99%, de). The utility of this flexible method has been demonstrated in the synthesis of D-ribo-phytosphingosine 1, its two derivatives 18 and 29. Moreover, a practicable synthetic route for synthesis of various sphingolipids, ceramides, alpha-galactosylceramides and their derivatives is also described. (c) 2012 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.tet.2012.05.120
  • 作为产物:
    描述:
    1-溴十一烷三苯基膦乙腈 为溶剂, 以69.2%的产率得到(1-十一烷基)三苯基鏻溴化物
    参考文献:
    名称:
    5-Hexadecanolide、6-Acetoxy-5-hexadecanolide和Tanikolide的合成
    摘要:
    描述了 5-hexadecanolide (1)、6-acetoxy-5-hexadecanolide (2) 和 tanikolide (3) 的全合成。选择 1-溴十一烷 (4) 和 5-苄基-1-戊醛 (5) 作为起始材料。Wittig 烯化和格氏加成 4 和 5 提供了 16 碳骨架,其经过一系列官能团转化得到 δ-内酯衍生物 1、2 和 3。
    DOI:
    10.1002/jccs.200100112
  • 作为试剂:
    描述:
    正庚基三苯基溴化磷1-溴代庚烷三苯基膦正丁基锂5-氧代戊酸乙酯 、 在 (1-十一烷基)三苯基鏻溴化物氮气 作用下, 以 乙醚正己烷 为溶剂, 反应 0.17h, 以to give ethyl (Z)-dodec-5-enoate as a yellow oil (8.6 g)的产率得到(Z)-ethyl dodec-5-enoate
    参考文献:
    名称:
    Pheromones
    摘要:
    式子为##STR1##的化合物,其中R代表氢、甲酰或碳数为2至25的脂肪酰基,R'代表碳数为1至35的烷基,可作为蚊子的引诱剂,蚊子会被吸引到该地点,然后蚊子及其卵或幼虫被摧毁。
    公开号:
    US04844892A1
点击查看最新优质反应信息

文献信息

  • A convenient chiron approach to (4R,5R)-5-hydroxyalkylbutan-4-olides and the corresponding 7-oxa analogues from d-(+)-mannitol via an advanced common precursor: syntheses of (−)-muricatacin, 7-oxa-(−)-muricatacin, (4R,5R)-(−)-5-hydroxy-4-decanolide, and (4R,5R)-(−)-7-oxa-5-hydroxy-4-dodecanolide
    作者:Sandip Chatterjee、Avrajit Manna、Tanurima Bhaumik
    DOI:10.1016/j.tetasy.2014.11.001
    日期:2014.12
    An efficient and concise chiron approach toward the synthesis of ()-muricatacin and its unnatural 7-oxa analogue starting from commercially available and inexpensive d-(+)-mannitol via an advanced common chiral precursor has been described. In addition, (4R,5R)-()-5-hydroxy-4-decanolide and (4R,5R)-()-7-oxa-5-hydroxy-4-dodecanolide were also synthesized to show the versatility of this synthetic
    朝向的合成的有效和简洁的方法Chiron公司( - ) - muricatacin和由市售且廉价d其非天然-7-氧杂类似物起始- (+) -甘露糖醇通过先进常见的手性前体进行了说明。另外,(4 - [R,5 - [R )- ( - ) - 5-羟基-4-癸并(4 - [R,5 - [R )- ( - ) - 7-氧杂-5-羟基-4- dodecanolide还合成到展示了这种综合策略的多功能性。该方法涉及一个共同的手性中间体,由d制备的转化- (+) -六步中只有两个步骤甘露醇,各种靶分子。
  • SRS-A antagonists
    申请人:Lilly Industries Limited
    公开号:US04513005A1
    公开(公告)日:1985-04-23
    There are described pharmacologically active compounds, useful in the treatment of allergic/inflammatory disorders involving SRS-A as causal mediator and which, in free acid form, are of formula I, ##STR1## in which R.sub.1 is (i) an aliphatic, saturated or unsaturated hydrocarbyl radical of up to 20 carbon atoms, unsubstituted or substituted by at least one substituent selected from halogen, hydroxy, C.sub.3-6 alkoxy, C.sub.3-6 cycloalkyl, aryl or heteroaryl, the cycloalkyl, aryl or heteroaryl being unsubstituted or substituted by at least one substituent selected from hydroxy, halogen and alkyl, alkenyl or alkynyl of up to 10 carbon atoms, (ii) cycloalkyl of 3 to 8 carbon atoms unsubstituted or substituted by alkyl, alkenyl or alkynyl of up to 16 carbon atoms, or (iii) aryl or heteroaryl, unsubstituted or substituted by hydroxyl, C.sub.1-4 alkoxy, halogen or alkyl, alkenyl or alkynyl of up to 16 carbon atoms; and R.sub.2 is (i) alkyl, cycloalkyl or alkenyl of up to 10 carbon atoms, unsubstituted or substituted by one or more substituents selected from aryl, cycloalkyl, halogen, hydroxy, NHR.sub.3 and COX, where R.sub.3 is H, C.sub.1-4 alkyl, aryl or an amino acid residue or COX, and X is OH, C.sub.1-4 alkyl, NH.sub.2 or an amino acid residue, or (ii) aryl or heteroaryl, unsubstituted or substituted by one or more substituents selected from C.sub.1-4 alkyl, C.sub.1-4 alkoxy, C.sub.2-5 acyl, halogen, hydroxy, carboxy, nitro, trihalomethyl, phenyl, C.sub.1-4 acylamino and NHR.sub.4, where R.sub.4 is hydrogen or C.sub.1-4 alkyl; and Y is --S--, --SO-- or --SO.sub.2 --, with the proviso that when --YR.sub.2 is glutathionyl, cysteinyl or cysteinylglycinyl, then R.sub.1 is other than an unsubstituted alkatetraenyl or alkapentaenyl radical of 12 to 16 carbon atoms.
    描述了在涉及SRS-A作为因果介质的过敏/炎症性疾病治疗中有用的药理活性化合物,这些化合物在游离酸形式下的化学式为I,其中R.sub.1是(i)具有多达20个碳原子的脂肪烃基、饱和或不饱和的烃基,未取代或被至少一种取代基取代,所述取代基选自卤素、羟基、C.sub.3-6烷氧基、C.sub.3-6环烷基、芳基或杂环芳基,所述环烷基、芳基或杂环芳基未取代或被至少一种取代基取代,所述取代基选自羟基、卤素和多达10个碳原子的烷基、烯基或炔基,(ii)具有3至8个碳原子的未取代或被多达16个碳原子的烷基、烯基或炔基取代的环烷基,或(iii)芳基或杂环芳基,未取代或被羟基、C.sub.1-4烷氧基、卤素或多达16个碳原子的烷基、烯基或炔基取代;R.sub.2是(i)多达10个碳原子的烷基、环烷基或烯基,未取代或被一个或多个取代基取代,所述取代基选自芳基、环烷基、卤素、羟基、NHR.sub.3和COX,其中R.sub.3为H、C.sub.1-4烷基、芳基或氨基酸残基或COX,X为OH、C.sub.1-4烷基、NH.sub.2或氨基酸残基,或(ii)芳基或杂环芳基,未取代或被一个或多个取代基取代,所述取代基选自C.sub.1-4烷基、C.sub.1-4烷氧基、C.sub.2-5酰基、卤素、羟基、羧基、硝基、三卤甲基、苯基、C.sub.1-4酰胺基和NHR.sub.4,其中R.sub.4为氢或C.sub.1-4烷基;Y为--S--、--SO--或--SO.sub.2--,但当--YR.sub.2为谱胱甘肽、半胱氨酸或半胱氨酰甘氨酸时,R.sub.1不是12至16个碳原子的未取代的α-四烯基或α-五烯基基团。
  • An Efficient Catalytic Asymmetric Epoxidation Method
    作者:Zhi-Xian Wang、Yong Tu、Michael Frohn、Jian-Rong Zhang、Yian Shi
    DOI:10.1021/ja972272g
    日期:1997.11.1
    This article describes a highly effective catalytic asymmetric epoxidation method for olefins using potassium peroxomonosulfate (Oxone, Dupont) as oxidant and a fructose-derived ketone (1) as catalyst. High enantioselectivies have been obtained for trans-disubstituted and trisubstituted olefins which can bear functional groups such as tributylsilyl ether, acetal, chloride, and ester. The enantiomeric
    本文描述了一种使用过一硫酸钾(Oxone,Dupont)作为氧化剂和果糖衍生的酮 (1) 作为催化剂的烯烃高效催化不对称环氧化方法。对于可以带有三丁基甲硅烷基醚、缩醛、氯化物和酯等官能团的反式二取代和三取代烯烃,已经获得了高对映选择性。顺式烯烃和末端烯烃的对映体过量还不高。目前的环氧化反应表明,提高 pH 值后催化剂效率显着提高。机理研究表明,环氧化主要通过螺过渡态进行,这为预测反应的立体化学结果提供了模型。平面过渡态可能是主要的竞争途径。
  • Synthesis and structure-activity relationship studies of a series of 5-aryl-4,6-dithianonanedioic acids and related compounds: a novel class of leukotriene antagonists
    作者:Carl D. Perchonock、Irene Uzinskas、Mary E. McCarthy、Karl F. Erhard、John G. Gleason、Martin A. Wasserman、Roseanna M. Muccitelli、Jeris F. DeVan、Stephanie S. Tucker
    DOI:10.1021/jm00158a021
    日期:1986.8
    especially good activity. Conformational restriction of either the polar region or lipid tail produced compounds devoid of activity. A number of selected analogues were also evaluated in vivo as antagonists of LTD4-induced bronchoconstriction in the guinea pig. The data established these compounds as a novel class of leukotriene antagonists with potential utility for the treatment of asthma and other immediate
    已经制备了一系列5-炔基-和5-芳基-4,6-二硫代癸二酸和相关化合物以评估白三烯拮抗剂活性。炔基化合物是通过相应的炔属缩醛通过硫缩醛交换制备的。芳基衍生物是由适当的苯甲醛合成的,其中大多数是通过以下三种通用途径之一制备的:迈耶的恶唑啉法,钯偶联法和羟基苯甲醛烷基化。在体外检查了这些类似物拮抗LTD4诱导的豚鼠气管平滑肌收缩的能力,并与[3H] LTD4竞争豚鼠肺膜上的受体位点。这项研究发现了许多构效关系。脂质尾部和极性区域中的两个亚甲基的最佳链长为10-12个原子(或其等价物)。在芳族系列中,邻位和间位取代的化合物具有可比的活性,而对位衍生物则无活性。芳香环和脂质尾部的取代通常具有良好的耐受性,末端苯基(6)和乙炔(33)类似物的活性特别好。极性区或脂质尾部的构象限制产生了缺乏活性的化合物。在体内也评估了许多选择的类似物作为豚鼠中LTD4诱导的支气管收缩的拮抗剂。数据确定这些化合物为一类
  • Synthesis and Structure-Activity Relationships of Phaffiaol and Related Antioxidants.
    作者:Shuji JINNO、Takaaki OKITA
    DOI:10.1248/cpb.46.1688
    日期:——
    Total synthesis of a novel long chain alkyl phenol, phaffiaol (1), a potent antioxidant isolated from Phaffia rhodozyma, was achieved via three reaction steps starting from 3, 5-dibromosalicylaldehyde (2). We also prepared several types of long chain alkyl phenol having different aromatic rings or different carbon length, and evaluated their antioxidative activity using the rabbit erythrocyte membrane ghost system. Amongst these compounds, the novel methoxy phenol derivatives (6c, d, 7) having a heptadecyl moiety at the ortho-position to the hydroxy group, were approximately 2 times more active than α-tocopherol. In addition, 4-methoxy-2-pentadexylphenol (10h), which has a 15-carbon length in the side chain moiety, showed the maximum activity.
    通过从3,5-二溴水杨醛(2)开始的三个反应步骤,实现了从Phaffia rhodozyma中分离得到的强效抗氧化剂phaffiaol(1)这一新型长链烷基酚的完全合成。我们还制备了几种具有不同芳环或不同碳链长度的长链烷基酚,并通过兔红细胞膜系统评估了它们的抗氧化活性。在这些化合物中,具有十七烷基侧链且位于羟基邻位的甲氧基酚衍生物(6c、d、7)的活性约为α-生育酚的两倍。此外,侧链具有15个碳原子的4-甲氧基-2-十五烷基酚(10h)显示出最高的活性。
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫 龙胆紫 齐达帕胺 齐诺康唑 齐洛呋胺 齐墩果-12-烯[2,3-c][1,2,5]恶二唑-28-酸苯甲酯 齐培丙醇 齐咪苯 齐仑太尔 黑染料 黄酮,5-氨基-6-羟基-(5CI) 黄酮,6-氨基-3-羟基-(6CI) 黄蜡,合成物 黄草灵钾盐